Health effects of non-persistent EDCs, characterised by short half-lives and fast metabolism, are challenging to be detected in the general population due to EDC intra-individual variability, general ubiquity and latent effects. Omics are becoming increasingly common to detect subtle early biological changes before the apparition of clinical symptoms and to explore EDC-related toxic mechanisms increasing the biological plausibility of epidemiological associations. This scoping review systematically summarises the application of omics technologies in epidemiological studies that assessed biological effects associated with non-persistent EDC exposure, in order to identify potential gaps and set priorities for future exposome research planning to use omics. Ninety-eight human studies (2004-2021) were identified through database searches (PubMed, Scopus), and citation chaining. Most of the studies focused on one family of EDCs, including phthalates (34 studies), phenols (19), and PFASs (17), while PAHs and pesticides were studied less frequently (12 and 3, respectively). The sample sizes ranged from 10 to 12,476 (median = 160), involving non-pregnant adults (42 studies) or pregnant women (34), or children/adolescents (27). Several studies included occupational workers (12) and/or high-exposed groups (10) focusing on PAHs, PFASs, and pesticides while studies on phenols (30) and phthalates (46) were performed on the general population only. Omics measured included metabolic profiles (44, including targeted analyses), gene expression (31) and DNA methylation (12). Overall, studies had common limitations, in particular the small sample size, the cross-sectional designs, and single sampling for exposure biomonitoring that could explain the lack of replication across studies. We also identified clear research gaps such as the lack of omic studies on currently used pesticides (organophosphate pesticides or pyrethroids). Standardising research methods and reporting are recommended to facilitate result comparison. Future studies should consider differences in study methodology, use of prospective design, influence from co-exposure confounding and measurement errors. scoping review, endocrine disruptors, omics